Enhertu for Breast Cancer: Uses, Dosage, and Cost

Enhertu contains the active drug fam-trastuzumab deruxtecan-nxki. It is an FDA-approved HER2-directed antibody and topoisomerase inhibitor conjugate. Commercially supplied as 100 mg vials in the market, it may also be known as trastuzumab deruxtecan, or T-DXd. Enhertu 100 mg is developed by Daiichi Sankyo and is promoted by AstraZeneca (AZ) globally.

Enhertu Uses for Breast Cancer: Enhertu is approved by the FDA for the treatment of adults with breast cancer that is either:

HER2-positive: These are tumors that grow quickly because of higher levels of a protein named  HER2 or human epidermal growth factor receptor 2. As per Breast Cancer Foundation, 15-20 % of breast cancers are HER2-positive, and these cancers tend to progress faster.

HER2-low: This newer term basically describes tumors that have HER2 but are not sufficient to be considered positive. Earlier these tumors would have been classified as HER2-negative. Now up to 60 percent of breast cancers are HER2-low.

More specifically, the medicine Enhertu injection is considered when these tumors are either metastatic (meaning it has spread from their initial location to distant body parts), or unresectable (meaning they can't be removed surgically).

Prior to starting Enhertu, patients must also have already been treated with other therapies (anti-HER2 therapy for HER2 +Ve cancer, or chemotherapy for HER2-low) for metastatic cancer, or had a recurrence within six months following completing these previous therapies.

Other Uses of Enhertu (fam-trastuzumab deruxtecan-nxki):

 Enhertu 100 mg injection may also be given to individuals who have:

• NSCLC, that has a specific mutation named HER2, which is unable to be removed with surgery or has metastasized, and has already been treated.
• HER2 +Ve gastric or gastroesophageal junction adenocarcinoma stomach cancer that has spread and has already been treated.

Enhertu Dosage & Administration:

Enhertu is typically administered intravenously (IV) through a method known as infusion therapy. It is an ADC, a type of targeted medicine, meaning it travels to the tumor and releases chemo to the cells that produce excess HER2, directly destroying the cells that cause harm to the body.  A dose of 5.4 mg/kg of body weight is typically given once every 21 days. Treatment duration may vary, with 7 months being the midrange treatment.

Enhertu Injection Cost & Availability:

Enhertu cost in India is mostly influenced due to the lack of easy access. Patients can consider several options that are cost-effective. Enhertu is a lifesaving medicinal product that is not (yet) available in India. But can be legally accessed from an experienced service provider Indian Pharma Network (IPN). We are specialized in delivering specialty medicinal products like sourcing Enhertu 100 mg injection in India.

Kindly WhatsApp/Call: +91 9310090915 or dial our TOLL-FREE Number: 1800-889-1064 to buy Enhertu Online in India and other countries where the medicine is not (yet) approved.

Atriance Suppliers in India

For the proper handling and disposal of cytotoxic anti-tumour pharmaceuticals, the following procedures should be followed: 

Staff members must receive training on handling and transporting the medication.

You can now buy Atriance injection online in India through The Indian Pharma Network at an affordable price by going to our website at https://www.indianpharmanetwork.in/. We are a team of highly skilled specialists with more than 20 years of expertise in distributing speciality pharmaceuticals.

Atriance: Distributors in India

Despite the low Atriance injection price, this medicine is under closer observation. Healthcare professionals should report any potential harmful responses. There were insufficient numbers of patients 65 and older in clinical investigations using nelarabine to ascertain whether their responses differed from those of younger patients. Nelarabine was administered to a child patient in clinical tests at a dose of 75 mg/kg daily for 5 days, to 5 adult patients at a dose of 60 mg/kg (roughly 2,400 mg/m2) daily for 5 days, and to 2 additional adults on days 1, 3, and 5. For more information on Atriance, contact us by email at info@indianpharmanetwork.in.

Atriance: An FDA-approved medication

The FDA approved the medicine Nelarabine in 2005. According to an exploratory analysis, getting older—particularly older than 65—seemed linked to a higher incidence of neurological adverse events. Although it is packaged as Atriance 250mg 50 ml, overdose can occasionally occur. However, there haven't been any overdose reports. Nelarabine overdose is likely to result in fatal myelosuppression, severe neurotoxicity, and other side effects. Two patients who received 2200 mg/m2 on days 1, 3, and 5 every 21 days experienced significant grade 3 ascending sensory neuropathy. 

FDA approves Tibsovo (ivosidenib)

 Adult patients with susceptible IDH1 mutations discovered by an FDA-authorized test are treated with Tibsovo, an FDA-approved IDH1 inhibitor approved in 2018. One can take Tibsovo with or without meals. A high-fat meal should not be consumed with tibsovo since the concentration will increase. It is not recommended to split or divide Tibsovo tablets. Take Tibsovo pills orally at the same time each day. Wait until the following dosage is planned if you vomit and miss a Tibsovo dose. 

Tibsovo has the following drug interactions that patients should be aware of before using. If you require any further information, consult your doctor. Please get in touch with The Indian Pharma or send an email to info@indianpharmanetwork.in for further details about the Tibsovo cost. 

Tibsovo: Applications 

It is possible to get tibsovo tablets. Till the disease becomes worse or there is serious toxicity, Tibsovo should be used once a day. 

•  A kind of blood cancer called acute myeloid leukemia (AML). 

Recurrent or refractory AML should not be treated in patients over 75 with comorbidities prohibiting extensive induction chemotherapy. 

• Patients who had previously had therapy for either locally advanced or metastatic cholangiocarcinoma were found to have the illness. 

This is accessible with a valid prescription and from a reliable vendor like Indian Pharma Networks. Any generic and creative provider with the necessary authorization, a legitimate and acknowledged prescription, and adherence to the requirements may offer the drug. As one of the most dependable and trustworthy generic pharmaceutical suppliers, Indian Pharma Networks offers you to buy Tibsovo online at incredibly low costs. 

Tibsovo: Restricted Use 

Along with its advantages, tibsovo 250 mg has a few warnings and precautions, which are as follows: 

Checking for QTc interval prolongation should be done using minerals and electrocardiograms. Reducing or pausing the dosage, starting the dose, or stopping Tibsovo altogether should be done if QTc interval prolongation happens. 

Look for new motor and sensory abnormalities in individuals who may have Guillain-Barre syndrome (GBS) and the accompanying signs and symptoms. 

Tibsovo: Prohibited with other Drugs 

• Reduce your Tibsovo dose if you take a strong or moderate CYP3A4 inhibitor. Look for indications of a prolonged QTc interval in the individuals. 
• It is best to avoid using Tibsovo concurrently if you are a CYP3A4 inducer.
• Avoid using Tibsovo concurrently when using sensitive CYP3A4 substrates. 
• No medicine that lengthens QTc should be administered with tibsovo. If coadministration 
• is inevitable, patients should be closely watched for a heightened risk of QTc interval prolongation. 
• Your doctor may recommend a corticosteroid or hydroxyurea medication while watching you in the hospital if you exhibit symptoms of differentiation syndrome. 

This extremely powerful medication is freely available and may be purchased from any reputable vendor. Due to its low cost, Tibsovo is very simple to include in treatment programs in India. For more information on how much Tibsovo costs in India, please contact us at https://www.indianpharmanetwork.in/contact-us/. 

Tibsovo: Undesirable Effect 

Tibsovo is the brand name for ivosidenib-containing film-coated tablets. Among the inactive components are colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate.

• Fatigue, arthralgia, leukocytosis, diarrhea, edema, nausea, dyspnea, mucositis, and irregular ECG readings were the most frequent side effects in AML patients (20%). Rash, cough, reduced appetite, myalgia, constipation, and pyrexia are some of the symptoms of QT prolongation. 
• Hemoglobin decrease, calcium drop, sodium drop, magnesium drop, uric acid drop, potassium drop, alkaline phosphatase drop, aspartate aminotransferase drop, phosphate drop, and creatinine drop were the most prevalent laboratory abnormalities in AML patients (20%). 

This effective medication is available in India, and the price of Tibsovo is economical. 

Tibsovo: Availability in India 

Ivosidenib, a little medication, prevents the mutant isocitrate dehydrogenase 1 (IDH1) enzyme from functioning. The most prevalent mutations in AML patients are R132H and R132C.

Ivosidenib considerably decreased the dosage necessary to inhibit a variety of IDH1 R132 mutants in vitro compared to wild-type IDH1. By blocking the mutant IDH1 enzyme, ivosidenib reduced 2HG levels and improved myeloid development in mice xenograft models of AML with an IDH1 mutation both in vitro and in vivo. Ivosidenib therapy reduced ex-vivo 2-HG levels, blast numbers, and the proportion of mature myeloid cells in blood samples from persons with AML and mutant IDH1. 

Due to the inexpensive cost, wide availability, and simplicity of adding Tibsovo price in India. Since we are the most reputable suppliers in the country, please contact Indian Pharma Network at https://www.indianpharmanetwork.in/contact-us/ for more information. 

Tibsovo: Indian Pharma Network 

The drug Tibsovo is approved by Indian Pharma Network for treating patients with acute myeloid leukemia and cholangiocarcinoma.

• In patients with cholangiocarcinoma, the most frequent adverse effects were tiredness, nausea, stomach pain, diarrhea, coughing, reduced appetite, ascites, vomiting, anemia, and rash. 
• In 10% of cholangiocarcinoma patients, low hemoglobin, elevated aspartate aminotransferase, and high bilirubin were the most prevalent laboratory abnormalities. 

Indian Pharma Network is a fast-growing pharmaceutical consultancy and service company that offers reliable network access to life-saving medicines.

kineret fda approved indications

Patients with moderately to highly active rheumatoid arthritis who have received at least one disease-modifying antirheumatic medication (DMARD) but failed to manage signs and symptoms or delay the course of structural damage are prescribed Kineret injection. These patients must be 18 years of age or older. 

It is also used to treat Neonatal-Onset Multisystem Inflammatory Disease (NOMID). Only with a prescription can one receive Kineret, and only a licensed physician should initiate and oversee treatment. 

Kineret: Process to Administer

There is a Kineret 100 mg/0.67 mL subcutaneous injectable solution available. Doses between 20 mg and 100 mg are possible with a graduated syringe. Kineret is injected subcutaneously, or beneath the skin, to deliver the medication. Kineret 100 mg once a day is the recommended dosage for treating rheumatoid arthritis, and it should be taken at around the same time each day. The dose for familial Mediterranean fever, Still's illness, and CAPS is based on the patient's weight and the severity of the ailment. Patients with CAPS must be at least 8 months old and 10 kg in weight to undergo therapy. Take 100 mg of COVID-19 once a day for 10 days.      

FDA-Approved Medication 

Kineret was given the go-ahead to treat RA and Cryopyrin-Associated Periodic Syndromes (CAPS) on November 14, 2001. Human interleukin-1 receptor antagonist (IL-1Ra) is marketed as Kineret (anakinra) and is available in the recombinant, non-glycosylated form. A single methionine residue has been added to the amino terminus of Kineret, which makes it different from native human IL-1Ra. Kineret has a molecular weight of 17.3 kilodaltons and 153 amino acids. It is created utilizing a bacterial expression system from E. coli and recombinant DNA technologies.

Kineret: Price in India

Glass single-use syringes with 27 gauge needles are used to deliver Kineret. Each prefilled glass syringe has a 0.67 mL volume and weighs 100 milligrammes of anakinra. Anakinra is included in 100 milligrams of the whole syringe. A 4 × 7 syringe dispensing pack with 28 syringes is available to administer Kineret.

Kineret is also offered in a single 7-syringe dispensing pack. Storage. Kineret should be kept between 2 and 8 degrees Celsius or 36 and 46 degrees Fahrenheit. It must be protected from light, not frozen, or disturbed.Kineret injection is offered reasonably and cost-effectively; therefore, we provide you with the lowest Kineret cost.

Kineret: Available as Injectables

The main component of Kineret is the immunosuppressive medication anakinra. Immunosuppressive drugs work by reducing immune system function. An artificial replica of a human protein called "human interleukin 1 receptor antagonist," anakinra blocks the body's interleukin 1 receptors. High levels of this interleukin production are seen in rheumatoid arthritis patients, which causes joint inflammation and, ultimately, joint damage. Additionally, it fuels the inflammation connected to CAPS, familial Mediterranean fever, and Still's illness. There is no binding site left because anakinra prevents the action of interleukin 1 by attaching to the receptors where interleukin 1 would ordinarily attach. The indications and symptoms of many ailments are eventually relieved.

Indian Pharma Network provides it, which you may get at a fair price. Contact us for more information on the kineret injection and price.

Undesirable effects

• Rheumatoid Arthritis (RA) The most prevalent side effects (incidence 5%) are injection site reactions, rheumatoid arthritis aggravation, upper respiratory tract infections, headaches, nausea, diarrhea, sinusitis, arthralgia, and stomach pain.
• NOMID

The most commonly reported adverse effects during the first six months of therapy were injection site reactions, headaches, vomiting, arthralgia, pyrexia, and nasopharyngitis.

Prohibited Usage

There have been no studies on medication interactions involving humans. The clearance or toxicologic profiles of either medication did not significantly change after methotrexate and Kineret administration to rats in toxicologic and toxicokinetic studies. 

TNF Blocking Agents: Studies have shown that patients taking concurrent Kineret and etanercept medication had more serious infections than patients getting etanercept alone. In 2% of individuals taking Kineret and etanercept concurrently, neutropenia (ANC 1 x 109/L) developed. Combining Kineret with TNF-blocking drugs is not recommended.

Kineret should only be used under the supervision of a licensed medical professional, and a prescription is required to obtain it. The  Kineret injection cost is moderate and fair; for more details, contact Indian Pharma Network. 

Dosage Strength

When a young person has NOMID, Kineret is advised for geriatric use. Due to the increased prevalence of infections in the senior population, care should be given while treating the elderly.

Renal dysfunction: Because this medicine is believed to be mostly removed through the kidneys, individuals with impaired renal function may be more vulnerable to negative drug responses. 

Kineret can only be obtained with a prescription; only a qualified medical professional should start and manage treatment. The cost of Kineret injection is reasonable and accessible; for additional details, see Kineret 100mg price.

Restricted Use 

Stop using the RA medication if a serious infection develops. Patients with NOMID should weigh the potential risks of quitting Kineret therapy against the possibility of a NOMID flare. Starting Kineret shouldn't be done by patients who have active infections. 

• Combining it with drugs that block tumor necrosis factor (TNF) is not recommended.
• There have been recorded cases of angioedema and anaphylactic reactions, among other hypersensitivity events. 
• Kineret treatment has not been demonstrated to affect the development of cancer or active or persistent infections.
• Live vaccines shouldn't be given combined with Kineret.
•  Before beginning Kineret therapy, neutrophil levels should be assessed every three months while on Kineret and then every six months for up to a year afterward. 
• The cost of Kineret 100 mg is fair and affordable; for more information, contact Indian Pharma Network by going to our website, https://www.indianpharmanetwork.in/. 

Retevmo Treatment for medullary thyroid cancer

Availability in India

The active element in the cancer medication Retevmo is sepercatinib. Adult patients with one of the following conditions are treated with it: locally advanced or metastatic non-small cell lung cancer (NSCLC) with a RET gene fusion; locally advanced or metastatic solid tumors with a RET gene fusion; advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation. It exerts its effect via inhibiting kinase.It is also used in pediatric patients over 12 with advanced medullary thyroid cancer.

Retevmo cost in India is inexpensive and can be bought with a valid prescription, so you may get it from various sellers and spend less for the medication. Indian Pharma is one of the most reputable and trusted generic medicine manufacturers. 

Recommended Dosage

Selpercatinib is contained in Retevmo. The patient is chosen based on the presence of a certain RET gene mutation (MTC) or transfection gene rearrangement (NSCLC or thyroid). The dosage of retevmo is regulated by body weight. As a result, before beginning Retevmo medication, the patient's body weight is examined, and the Retevmo dosage is changed as needed. If the patient weighs less than 50 kg, the dose should be 120 mg; if the patient weighs 50 kg or more, the dose should be 160 mg. This medicine requires a prescription, and the therapy should be initiated and overseen by a certified medical specialist.

Dosage & Administration

Retevmo must be administered orally twice a day, approximately every 12 hours until disease progression or severe toxicity is noted. This drug can be taken with or without food unless combined with a proton pump inhibitor. It should be emphasized that Retevmo capsules should not be crushed or chewed but should instead be swallowed whole. If a dose is missed, it should be taken at least 6 hours after the previous dose. Please read the package leaflet or contact us at https://www.indianpharmanetwork.in/contact-us/  if you have any questions about missing Retevmo doses. 

An FDA approved drug

The drug Retevmo conatins Selpercatinib, approved by the FDA in 2020 for treating non-small cell lung cancer. SELPERCATINIB price is reasonable and one can buy this medicine from any liecnesed supplier. This drug is a RET inhibitor that belongs to the tyrosine kinase inhibitor class of cancer medicines. Retevmo inhibits the activity of abnormal proteins in the body. The body produces these proteins due to changes in the RET gene. certain abnormal proteins in people with certain mutations can lead to uncontrolled cell proliferation and malignancy, culminating in tumor formation. Selpercatinib reduces cancer cell growth and spread by blocking proteins.

Common side effects

Despite being a potent cancer treatment, Retevmo has some adverse effects that can be moderate or fatal. The most common adverse reactions seen after using Retevmo are loss of appetite, headache, dizziness, prolonged QT interval, high blood pressure, abdominal pain, diarrhea, nausea, vomiting, constipation, dry mouth, rash, fever, tiredness, oedema, bleeding, and laboratory blood tests showing changes in liver enzymes, decreased platelet and white blood cell count, decreased magnesium, and increased creatinine. One out of every 10 people taking this drug will experience these side effects.

Retevmo's most common main adverse effects are stomach pain, hypersensitivity, diarrhea, and blood tests that show elevations in liver enzymes, indicating liver stress. 

Drug Interactions

Certain drug interactions should be avoided because they can affect the Retevmo dose. Retevmo 40mg/80mg capsules have Some interactions, which are as follows:

Coadministration of acid-reducing medicines should be avoided since it reduces plasma selpercatinib levels and may decrease Retevmo anti-tumor activity.  

Coadministration of strong and moderate CYP3A inhibitors should be avoided since it raises selpercatinib levels in the blood and increases the risk of side effects.

 Strong and moderate CYP3A inducers: Avoid co administration since it lowers drug plasma concentration, which reduces Retevmo's anti-tumor activity.

Substrates for CYP2C8 and CYP3A: They increase plasma Retevmo levels. Co Administration should be avoided at all costs. Adjust the substrate dosage as stated on the product label if coadministration is unavoidable.

Certain P-gp Substrates: it improves Retevmo concentration as well. Coadministration should thus be avoided. Adjust the substrate dosage as stated on the product label if coadministration is unavoidable.

Retevmo: Summary of the medicine

Retevmo works by inhibiting kinases. The chemical formula for selpercatinib is C29H31N7O3, and its molecular weight is 525.61 g/mol. Selpercatinib is a white to light yellow powder that absorbs moisture from the air and is mildly hygroscopic. Selpercatinib's water solubility is pH dependent. It is only marginally soluble at low pH and virtually insoluble at neutral pH. 40 mg and Retevmo 80 mg hard gelatin capsules are available for oral use. Click here to learn more about selpercatinib and its numerous applications/pharmacological actions. Please contact us by phone or text at https://www.indianpharmanetwork.in/contact-us/. 

Storage & Handling of the medicine 

Microcrystalline cellulose and colloidal silicon dioxide are inactive ingredients in each medicine capsule. The 40 mg pill shell contains gelatin, titanium dioxide, ferric oxide black, and black ink. Patients must read the ingredients and notify their doctor if they cause allergies. Furthermore, the active ingredient is selpercatinib. Keep Retevmo capsules at room temperature, between 68°F and 77°F (20°C and 25°C). A Retevmo 40 mg bottle has 60 capsules.

Retevmo: Price in India

Pregnancy- Based on animal research and the mechanism of action of selpercatinib, it has been discovered that when taken by pregnant women, it can actively cause fetal harm. Pregnant women should avoid taking it as a result. Seek medical attention in an emergency. 

Lactation- No information is available on the presence of selpercatinib in milk. There have been no studies on its metabolites in human milk, their effects on breastfed children, or their effects on milk production. However, due to the likelihood of serious adverse reactions in breastfed children, it is recommended that nursing be discontinued during and one week after the last dosage of Retevmo treatment to avoid severe effects on the child.

Retevmo: Clinical studies

One of the most important studies illustrates the effects of sepercatinib. The researchers discovered that Retevmo effectively shrinks tumor size in patients with cancer caused by RET gene abnormalities. Individual effects of selpercatinib (Retevmo) were investigated in this study but not compared to other drugs, dummy therapies, or placebo. The medication shrinks tumors in all cases, whether they are advanced non-small cell lung cancer, advanced thyroid cancer, or advanced medullary thyroid cancer. This great drug is available for purchase from any licensed supplier. Furthermore, the Retevmo cost is inexpensive and reasonable, allowing them to be easily adopted.

This efficient treatment for non-small cell lung and thyroid/medullary thyroid cancer is now available in India. Retevmo treatment can begin after being diagnosed using an FDA-approved test by competent medical health professionals and doctors. It is important to remember that, despite its inexpensive Retevmo price, Retevmo is not a prescription medication. For the sale and purchase of Retevmo, legal authorization and prescription are required. 

Oncaspar (Pegaspargase) Injection for Cancer Treatment

 Oncaspar: Indication and Usage 

Oncaspar is a cancer medication used to treat acute lymphoblastic leukemia (ALL), a cancer of white blood cells known as lymphoblasts, in adults and children. Oncaspar is prescribed in conjunction with other cancer medications. 

• Acute Lymphoblastic Leukaemia (ALL)-

Oncaspar is suggested as part of a multiagent chemotherapeutic routine for the first-line treatment of ALL patients.

•  Acute Lymphoblastic Leukaemia and Asparaginase Hypersensitivity

Oncaspar is used as part of a multiagent chemotherapy regimen to treat individuals with ALL who are allergic to native versions of L'Asparaginase. This efficient drug is widely available and may be obtained from any respectable vendor. In addition, the Oncaspar injection price in India is affordable. Visit  https://www.indianpharmanetwork.in/contact-us/ for further information.

 Dosage 

Oncaspar dosage strength includes Pegaspargase 3750 IU per 5 mL solution in a single-use vial. No more than 2,500 International Units/m2 intramuscularly or intravenously • Coagulopathy is possible. Carry out proper monitoring. More than once every 14 days. When administering intramuscularly, limit the volume at a single injection site to 2 mL; if the volume is larger than 2 mL, utilize multiple injection sites. 

For more information about the Dosage of the drug, you can call us at +91 9310090915; you can also write us at info@indianpharmanetwork.in 

Administration 

While administering Oncaspar intramuscularly, one should limit the volume at a single injection site to 2 mL. Multiple injection sites should be used if the volume to be delivered is larger than 2 mL. Only use one dose per vial; discard any unused product.

Oncaspar should be given intravenously over 1-2 hours in 100 mL of sodium chloride or dextrose injection 5% via an already running infusion. The solution should be used immediately after being diluted for intravenous usage. If immediate usage is not possible, keep the diluted solution refrigerated at 2°C to 8°C (36°F to 46°F). 

Keep infusion bags out of direct sunlight.

Through Indian Pharma Network, you can buy Oncaspar injections at an affordable price. The Indian Pharma Network facilitates access to new products in India. 

Contradiction

Even though oncaspar injections are readily available in the market under valid prescription, there are specific contradictions associated with the drug that needs to be checked before using the drug. 

• A history of severe allergic responses to Oncaspar
• Initial approval in the United States: 1994, history of L-asparaginase therapy for significant thrombosis 
• History of L-asparaginase therapy for pancreatitis 
• History of L-asparaginase therapy resulted in significant hemorrhagic episodes. 

Warnings and Precautions

If any of the following occur, one should stop using Pegaspargase injection-

• Anaphylaxis or other severe allergic responses-

Observe patients for 1 hour after receiving Oncaspar in a place equipped with resuscitation equipment and additional anaphylactic-treatment drugs (for example, epinephrine, oxygen, intravenous steroids, and antihistamines). In patients who have severe allergic reactions, discontinue Oncaspar. 

• Thrombosis-

Patients on Oncaspar may experience serious thrombotic events, including sagittal sinus thrombosis. In patients who have had major thrombotic events, discontinue Oncaspar. 

• Pancreatitis-

Examine people who have abdominal pain for signs of pancreatitis. In individuals with pancreatitis, discontinue Oncaspar.

Glucose intolerance, which might be permanent in some cases, can ensue. 

Adverse effects

Signs of liver problems, reduced blood clotting, high levels of fats in the blood, high levels of blood glucose, and low levels of white blood cells followed by fever are the most common side effects of Oncaspar (which may affect more than one in ten people).

Oncaspar should not be used in patients with severe liver illness, pancreatitis (including pancreatitis caused by past asparaginase treatments), or significant bleeding or substantial blood clots after asparaginase treatment.

You can visit us at https://www.indianpharmanetwork.in/about-us/ to get the product, as you can get Oncaspar in India at economical prices.

Mechanism of Action

Oncaspar's mechanism of action is assumed to be based on the selective death of leukemic cells caused by plasma asparagine depletion. Due to a lack of asparagine synthetase, some leukemic cells cannot synthesize asparagine and must rely on an exogenous source of asparagine to survive. Asparagine depletion, caused by therapy with the enzyme L-asparaginase, destroys the leukemic cells.

On the other hand, normal cells are less impacted by the deficiency since they can synthesize asparagine. 

This powerful pharmaceutical is on the market and may be obtained from any respectable vendor. Furthermore, the Oncaspar price in India is inexpensive. You can contact us at Indian Pharma Network can be reached at +91 93100 90915 

Description

Oncaspar (pegaspargase) is a covalently conjugated L-asparaginase (L-asparagine amidohydrolase) to monomethoxypolyethylene glycol (mPEG). L-asparaginase is a tetrameric enzyme generated by E. coli that consists of identical 34.5 kDa subunits.

Oncaspar is a clear, colorless, preservative-free isotonic sterile solution in phosphate-buffered saline with a pH of 7.3. In water for injection, USP, each milliliter includes 750 150 International Units of pegaspargase, dibasic sodium phosphate, monobasic sodium phosphate, and sodium chloride.

You can easily purchase this drug at effective rates as Pegaspargase injection cost in India, and it is economical through Indian Pharma Network.

 Use in Specific Population 

Pregnancy - Pregnancy Type C. Oncaspar has not been subjected to animal reproduction studies. It is also unknown whether Oncaspar can induce foetal damage or alter reproductive ability when provided to a pregnant woman. Oncaspar should only be given to a pregnant woman if necessary.

 Breastfeeding Mothers

Oncaspar is not known to be excreted in human milk. Oncaspar has the potential for severe adverse reactions in nursing infants, a choice should be made to terminate breastfeeding or discontinue the drug, taking the importance of the treatment to the mother into account. 

Overdosage

Three patients received an intravenous infusion of 10,000 International Units/m2 of Oncaspar. Liver enzyme levels in one patient slightly rose. A second patient experienced a rash 10 minutes after the infusion began, which was managed by administering an antihistamine and slowing down the infusion rate. A third patient did not have any negative responses. 

To know more about the drug or its overdose and Pegaspargase price in India, you can refer to the Indian Pharma Network, which connects patients with legitimate pharmaceutical suppliers, wholesalers, and dealers. One can check us out by clicking at  https://www.indianpharmanetwork.in/contact-us/ 

Acute Myeloid Leukemia Treatment

 The medicine Tibsovo contains ivosidenib, a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. Healthcare professionals recommend Tibsovo 250 mg Tablets in treating patients with acute myeloid leukemia (AML) and cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation. 

Acute Myeloid Leukemia: Blood Cancer

Acute myeloid leukemia (AML) is a rare cancer that affects your bone marrow and blood. It typically happens when certain genes or chromosomes mutate (change). AML usually affects people aged 60 and older but can also affect younger adults and children. 

Types of Acute Myeloid Leukemia are:

Myeloid leukemia: Cancer in cells that produce neutrophils, a white blood cell. Most people with AML have the myeloid leukemia subtype.

Acute monocytic leukemia (AML-M5): Cancer in cells that produce monocytes, white blood cells.

Acute megakaryocytic leukemia (AMLK): Cancer in cells that produce red blood cells or platelets.

Acute promyelocytic leukemia (APL): Cancer in promyelocytes (immature white blood cells) that keeps these cells from developing.

Prevalence

According to the Cleveland Clinic, Acute myeloid leukemia affects about 4 in 100,000 adults annually. Each year about 1,160 children receive an AML diagnosis. 

Symptoms of Acute myeloid leukemia

Early on, AML symptoms may feel like you have a cold or flu that won’t go away. Acute myeloid leukemia is aggressive. That means you quickly develop new and more noticeable symptoms such as:

• Dizziness.
• Easy bruising or bleeding, including frequent nosebleeds and bleeding gums.
• Fatigue.
• Feeling cold.
• Fever.
• Night sweats.
• Frequent infections or infections that don’t go away.
• Headaches.
• Loss of appetite.
• Unexplained weight loss.
• Pale skin.
• Shortness of breath.
• Swollen lymph nodes.
• Weakness.
• Bone, back or abdominal pain.
• Tiny red spots on your skin.
• Wounds or sores that don’t go away.

Diagnosis

Healthcare providers use several tests to diagnose AML, including genetic tests to identify AML type. Providers typically start with a physical examination. 

• Complete blood count (CBC).
• Peripheral blood smear.
• Bone marrow biopsy.
• Spinal tap
• Genetic tests

Treatments

Chemotherapy

There are three phases to chemotherapy for AML — induction, consolidation and maintenance. Some of the chemotherapy medicines for the treatment of AML are:

• Cytarabine
• Daunorubicin 
• Idarubicin 
• Azacitidine 
• Decitabine 
• Glasdegib 
• Venetoclax 

Consolidation therapy

Consolidation therapy kills any remaining cancerous cells. It lowers the risk of cancer recurrence (coming back). Most people receive high-dose cytarabine (Ara-C) or HiDAC five days each month for three or four months.

Maintenance therapy

Chemotherapy drugs for maintenance therapy may include:

• Azacitidine 
• Decitabine 
• Midostaurin 

Targeted therapy

Providers may use targeted therapy to treat AML that’s come back or hasn’t responded to chemotherapy:

Providers may use chemotherapy drugs midostaurin (Rydapt) or gilteritinib (Xospata) to treat AML patients with an FTL3 gene mutation. About 25% to 30% of people with AML carry this mutation.

They may use enasidenib (IDHIFA) or ivosidenib (Tibsovo) to treat people who have AML caused by a mutation of their X gene.